ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 6 for:    gum disease | Recruiting Studies | NIH

IFI16 is a Periodontitis Modulating Protein (IFI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03513497
Recruitment Status : Recruiting
First Posted : May 1, 2018
Last Update Posted : November 14, 2018
Sponsor:
Collaborator:
National Institute of Dental and Craniofacial Research (NIDCR)
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:

To characterize the expression of IFI16 and AIM2 in gingival tissues in an inflammatory response using an acrylic mouthguard (also referred to as a stent) induced bacteria overgrowth method.

Participants: A maximum of 72 Adult subjects will be recruited from the patients, students and staff at the University of North Carolina, as well as the general population in or near Chapel Hill NC.

Procedures (methods):

Medical history, demographics, (height/weight), urine based pregnancy test, vital signs (to include blood pressures, and pulse) standard dental clinical measures (to include plaque index, gingival index, bleeding on probing, and clinical attachment level), alginate impressions taken for fabrication of an acrylic stent (mouthguard), 2 gingival biopsies, 2 subgingival (below the gumline) plaque samples, and Scaling Root planing (SRP)/or adult prophylaxis


Condition or disease Intervention/treatment Phase
Severe Periodontitis Acute Inflammatory Response Other: Customized acrylic mouthguard Not Applicable

Detailed Description:
A total of 72 subjects will be enrolled. Specifically, a sufficient number of adults 18 years and older will be screened until 36 healthy (PPC-A) subjects and 36 subjects with severe periodontal disease (PPC-G) will be enrolled. Eligibility for study participation will be determined during the screening session. Barring dropout, subject participation will include 1 to 8 visits lasting over a maximum period of 42 days. The last 3 visits (visit 5-8) will depend on the individual need of the subject for providing SRP. Clinical data and medical history data will be collected at the screening visit to ascertain eligibility. All subjects will have dental plaque and a gingival biopsy collected at baseline. Enrolled subjects will be included in an experimental gingivitis model Stent-Induced Biofilm Overgrowth (SIBO) for 21 days. Individuals will return for safety checks every week during the 21-day period. At 21-days, plaque samples and a gingival biopsy will be collected. For diseased individuals SRP will initiate during the 21-day visit at the SIBO quadrant. Visit 6 (28 days) will include the post-biopsy follow up, prophylaxis (for healthy individuals) and SRP (diseased individuals). Subjects receiving SRP may have 2 additional visits (visit 7 at day 35 and visit 8 at day 42) for completing the SRP of all quadrants and will be dependent on individual need. Medical histories, demographics, height and weight, clinical and biological data described above will be recorded and stored on a secure server located at the University of North Carolina. Each participant enrolled into the study will have a unique identification number that has been stripped of any information that could be used by non-study members to identify the subject.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: IFI16 is a Periodontitis Modulating Protein
Actual Study Start Date : October 18, 2018
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2023

Arm Intervention/treatment
Experimental: Periodontal Profile Class (PPC-A)
Periodontally healthy participants (PPC-A) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
Other: Customized acrylic mouthguard
Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
Other Name: intraoral stent

Experimental: Periodontal Profile Class (PPC-G)
Participants with severe periodontal disease (PPC-G) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
Other: Customized acrylic mouthguard
Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
Other Name: intraoral stent




Primary Outcome Measures :
  1. Mean AIM2 mRNA fold change [ Time Frame: Baseline (Day 0), Visit 5 (Day 21) ]
  2. Mean IFI16 mRNA fold change [ Time Frame: Baseline (Day 0), Visit 5 (Day 21) ]
  3. Percentage of SIBO-induced AIM2 positive cells [ Time Frame: Baseline (Day 0), Visit 5 (Day 21) ]
  4. Percentage of SIBO-induced IIFI16 M2 positive cells [ Time Frame: Baseline (Day 0), Visit 5 (Day 21) ]

Secondary Outcome Measures :
  1. Percent periodontal pathogens by expression of AIM2 and IFI16 [ Time Frame: Baseline (Day 0), Visit 5 (Day 21) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects must have read, understood and signed an informed consent form.
  • Subjects must be able and willing to follow study procedures and instructions.
  • Subjects must be adult males or females with a minimum of 18 years (inclusive).
  • Subjects must present with at least 20 teeth in the functional dentition, excluding third molars.
  • Subjects must have at least 3 teeth in each posterior sextant
  • Subjects must be in good general health
  • Subjects must be in the healthy (PPC-A) or severe periodontitis (PPC-G) categories according to the PPC (1)

Exclusion Criteria:

  • If the sextants identified for the analysis has implants
  • All individuals who meet criteria for anti-infective prophylaxis prior to dental procedures
  • Chronic disease with oral manifestations including diabetes mellitus.
  • Current smoker or one that has stopped smoking less than 2 years prior to enrollment.
  • Gross oral pathology other than the periodontal disease.
  • Treatment with antibiotics for any medical or dental condition within 1 month prior to the screening examination.
  • Chronic treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, coumadin, non-steroidal anti-inflammatory drugs, aspirin) within one month of the screening examination.
  • Ongoing medications initiated less than three months prior to enrollment (i.e., medications for chronic medical conditions must be initiated at least three months prior to enrollment).
  • Significant organ disease including impaired renal function, heart murmur, history of rheumatic fever or valvular disease, or any bleeding disorder.
  • Individuals with prosthetic material used for intra-cardiac repair (e.g. for congenital heart disease), or intra-cardiac devices, cardiac transplant, infective endocarditis and individuals who have had previous infectious complications of prosthetic joint infections
  • Infectious diseases such as hepatitis, HIV or tuberculosis.
  • Anemia or other blood dyscrasias.
  • Anticoagulant therapy or drugs, such as heparin or warfarin.
  • Severe unrestored caries, or any condition that is likely to require antibiotic treatment over the trial.
  • Pregnant, or expect to become pregnant within the next several months.
  • Females of child-bearing capacity must be willing to have pregnancy test to confirm they are not pregnant.
  • Females of child-bearing capacity not using any form of contraceptive methods
  • Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03513497


Contacts
Contact: Kristy M Williams, BS 919-537-3420 kristyw@email.unc.edu
Contact: Sherrill T Phillips, BS 919-537-3422 sherrill_Phillips@unc.edu

Locations
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Kristy Williams, BS    919-818-4649    kristyw@email.unc.edu   
Contact: Sherrill T Phillips, BS    919-537-3422    sherrill_phillips@unc.edu   
Sponsors and Collaborators
University of North Carolina, Chapel Hill
National Institute of Dental and Craniofacial Research (NIDCR)
Investigators
Principal Investigator: Julie T Marchesan, DDS, PhD University of North Carolina, Chapel Hill

Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT03513497     History of Changes
Other Study ID Numbers: 18-0291
1K01DE027087-01 ( U.S. NIH Grant/Contract )
First Posted: May 1, 2018    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB) and executes a data use/sharing agreement with UNC.
Supporting Materials: Study Protocol
Time Frame: 9-36 months following publication

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of North Carolina, Chapel Hill:
Teeth
Periodontal disease
acute inflammatory response
stent-induced biofilm overgrowth
periodontal pathogens

Additional relevant MeSH terms:
Periodontitis
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases